Clinical Trial Update: A Study of SKB264 in Combination With Osimertinib Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutations, Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating SKB264 in combination with Osimertinib versus Osimertinib alone in EGFR-mutant non-squamous non-small cell lung cancer; currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SKB264
• TAGRISSO (osimertinib)

Snippet

Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Conditions: Non-Small Cell Lung Cancer | Phase 3 | Status: RECRUITING